Changes in Beneficial Ownership · 4
Iovance Biotherapeutics, Inc.
IOVANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2626734-2_4seq1.xml
Filing details
- Report period
- 2026-09-30
- Issuer
- IOVANCE BIOTHERAPEUTICS, INC.
- Issuer CIK
- 0001425205
- Trading symbol
- IOVA
Reporting owner 1
- Name
- Berkowitz Noah
- Reporting owner CIK
- 0001369900
- Relationship
- Officer
- Officer title
- Chief Medical Officer
- Address
- C/O IOVANCE BIOTHERAPEUTICS, INC., 300 ROUSE BLVD., PHILADELPHIA, PA, 19112
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy) | 14.82 | 2026-09-30 | A · Form 4 | 135,000 | A | 0.00 | [F1] | 2036-09-30 | Common stock | 135,000 | 135,000 | D |
| Restricted Stock Units | [F2] | 2026-09-30 | A · Form 4 | 180,000 | A | 0.00 | [F1] | [F1] | Common stock | 180,000 | 180,000 | D |
| Performance Stock Units | [F3] | 2026-09-30 | A · Form 4 | 135,000[F4] | A | 0.00 | [F5] | [F5] | Common stock | 135,000 | 135,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.↩ 1↩ 2↩ 3
- F2
- Each RSU represents a contingent right to receive one share of the Issuer's common stock.↩ 1
- F3
- Each performance stock unit ("PSU") converts into one share of the Issuer's common stock.↩ 1
- F4
- Up to 135,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain regulatory milestones.↩ 1
Signature 1
- Signed
- /s/ Noah Berkowitz
- Date
- 2026-10-02
Company context
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.